Explore the latest CDSCO-approved drugs, vaccines, and innovative therapies in India, including oncology, mental health, liver disease, and immunotherapy treatments approved in 2026.
India’s pharmaceutical sector continues to witness significant advancements with the approval of several innovative drugs, vaccines, and specialty therapies by the Central Drugs Standard Control Organization (CDSCO). These approvals aim to improve treatment options across various therapeutic areas, including oncology, psychiatry, women’s health, metabolic disorders, and infectious diseases.
Key Drug Approvals and Their Therapeutic Significance
Drug
Primary Indication
Importance
Brexpiprazole
Schizophrenia and Major Depressive Disorder
Provides an additional treatment option for mental health disorders.
Resmetirom
Non-Alcoholic Steatohepatitis (NASH)
Addresses a growing unmet need in liver disease management.
Ivosidenib
Acute Myeloid Leukemia (AML) and IDH1-Mutated Cancers
Offers targeted therapy for specific genetic mutations.
Linzagolix
Endometriosis and Uterine Fibroids
Expands treatment options in women’s health.
Polmacoxib
Osteoarthritis and Pain Management
Designed to provide anti-inflammatory benefits with improved safety.
Tucatinib
HER2-Positive Breast Cancer
Enhances targeted treatment strategies in oncology.
Vaccine and Biologics Approvals
Product
Manufacturer
Clinical Impact
Quadrivalent HPV Vaccine
Serum Institute of India
Helps prevent cervical cancer and HPV-related diseases through broader strain coverage.
Durvalumab
AstraZeneca
Strengthens immunotherapy options for multiple cancer indications.
Emerging Trends in CDSCO Approvals
Trend
Description
Targeted Oncology Therapies
Increasing approvals for precision medicines such as Ivosidenib and Tucatinib.
Women’s Health Innovations
New therapies like Linzagolix address unmet gynecological needs.
Mental Health Treatments
Brexpiprazole expands options for psychiatric care.
Vaccine Development
Domestic vaccine manufacturing continues to grow with approvals such as the Quadrivalent HPV Vaccine.
Gastrointestinal Therapies
Vonoprazan-based drugs offer new approaches for acid-related disorders.
Therapeutic Area Distribution
Therapeutic Area
Approved Products
Oncology
Ivosidenib, Tucatinib, Durvalumab
Psychiatry
Brexpiprazole
Women’s Health
Linzagolix
Hepatology
Resmetirom
Pain & Inflammation
Polmacoxib
Vaccines
Quadrivalent HPV Vaccine
Gastroenterology
Vonoprazan-Based Drugs
Conclusion
The latest CDSCO approvals highlight India’s commitment to improving healthcare access through innovative medicines, vaccines, and targeted therapies. From advanced cancer treatments and mental health medications to preventive vaccines and therapies for chronic diseases, these approvals are expected to enhance patient outcomes and strengthen the country’s pharmaceutical landscape in 2026.
